With an urban population exhibiting numerous risk factors for the silent killer hepatitis C, University of Maryland specialists have taken aim at the surprisingly prevalent virus with leading-edge research and community programs — just as FDA approval has been granted for a stunningly advanced therapy that could skyrocket the condition’s cure rate.